EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Association of Anti‐CCAR1 Autoantibodies With Decreased Cancer Risk Relative to the General Population in Patients With Anti–Transcriptional Intermediary Factor 1γ–Positive Dermatomyositis

David Fiorentino, Christopher A Mecoli iD, Tak Igusa, Jemima Albayda iD, Julie J Paik iD, Eleni Tiniakou iD, Brittany Adler, Andrew L Mammen iD, Ami A Shah, Antony Rosen, Lisa Christopher-Stine iD, Livia Casciola-Rosen iD

Arthritis & Rheumatology · 2023-07 · 75 (7) · 1238-1245

DOI: 10.1002/art.42474 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Arthritis & Rheumatology, online erschienen am 09.05.2023. Verfasst von David Fiorentino und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Stanford University School of Medicine, Redwood City, California. Hauptthemen laut MEDLINE: Dermatomyositis, Neoplasms, Rheumatic Diseases. Die Arbeit wurde bisher 39-mal zitiert (Crossref) und nennt 11 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIAMS NIH HHS, National Institute of Arthritis and Musculoskeletal and Skin Diseases.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To describe the disease specificity, clinical phenotype, and risk of cancer in dermatomyositis (DM) patients with autoantibodies against cell division cycle and apoptosis regulator protein 1 (anti‐CCAR1).

Methods

The frequency of anti‐CCAR1 autoantibodies was measured by enzyme‐linked immunosorbent assay in the serum of DM patients from 2 independent cohorts (Johns Hopkins and Stanford), with patients with several other rheumatic diseases and healthy controls used as comparators. Clinical features and the risk of cancer incidence relative to that in the general population were determined in anti‐CCAR1–positive DM patients.

Results

Anti‐CCAR1 antibodies were significantly associated with anti–transcriptional intermediary factor 1γ (anti‐TIF1γ) antibodies present in the serum of patients with DM: 80 (32%) of 252 anti‐TIF1γ–positive DM patients versus 14 (8%) of 186 anti‐TIF1γ–negative DM patients were positive for anti‐CCAR1 antibodies ( P < 0.001). Anti‐CCAR1 antibodies were not detected in any of the 32 serum samples from healthy controls, and were present at very low frequencies in the sera of patients with other rheumatic diseases: 1 (2.3%) of 44 patients with anti–hydroxymethylglutaryl‐coenzyme A reductase–positive necrotizing myopathy, 1 (2.3%) of 44 patients with inclusion body myositis, and 3 (6.5%) of 46 patients with systemic lupus erythematosus were positive for anti‐CCAR1 antibodies. Upon examining data on occurrence of cancer from the onset of DM onward, the observed number of cancers diagnosed in anti–TIF‐1γ–positive DM patients was significantly greater than expected in both cohorts, with a standardized incidence ratio (SIR) of 3.49 (95% confidence interval [95% CI] 2.39–4.92) in the Johns Hopkins cohort and a SIR of 4.54 (95% CI 3.04–6.52) in the Stanford cohort (each P < 0.001). DM patients who were both anti‐TIF1γ positive and anti‐CCAR1 positive had lower SIRs for cancer, with a SIR of 1.78 (95% CI 0.77–3.51) ( P = 0.172) in the Johns Hopkins cohort and a SIR of 1.61 (95% CI 0.44–4.13) ( P = 0.48) in the Stanford cohort.

Conclusion

Anti‐CCAR1 autoantibodies are specific for anti‐TIF1γ–positive DM. Their presence in anti‐TIF1γ–positive patients attenuates the risk of cancer to a level comparable to that seen in the general population. image

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DermatomyositisNeoplasmsRheumatic DiseasesHumansAutoantibodiesMediation Analysis

Substanzen

Autoantibodies

Autor:innen und Institutionen

  • Department of Dermatology, Stanford University School of Medicine, Redwood City, California.
  • Department of Medicine, Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, Maryland.
  • Whiting School of Engineering, Johns Hopkins University, Baltimore, Maryland.
  • Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, Maryland, and Muscle Disease Unit, Laboratory of Muscle Stem Cells and Gene Regulation, National Institute of Arthritis and Musculoskeleta…

ORCID-Profile: Christopher A Mecoli, Jemima Albayda, Julie J Paik, Eleni Tiniakou, Andrew L Mammen, Lisa Christopher-Stine, Livia Casciola-Rosen

Förderung

  • NIAMS NIH HHS
  • National Institute of Arthritis and Musculoskeletal and Skin Diseases

Zitieren

APA

Fiorentino, D., Mecoli, C. A., Igusa, T., Albayda, J., Paik, J. J., Tiniakou, E., Adler, B., Mammen, A. L., Shah, A. A., Rosen, A., Christopher-Stine, L., & Casciola-Rosen, L. (2023). Association of Anti‐CCAR1 Autoantibodies With Decreased Cancer Risk Relative to the General Population in Patients With Anti–Transcriptional Intermediary Factor 1γ–Positive Dermatomyositis. Arthritis & Rheumatology, 75(7), 1238-1245. https://doi.org/10.1002/art.42474

Vancouver

Fiorentino D, Mecoli CA, Igusa T, Albayda J, Paik JJ, Tiniakou E, et al. Association of Anti‐CCAR1 Autoantibodies With Decreased Cancer Risk Relative to the General Population in Patients With Anti–Transcriptional Intermediary Factor 1γ–Positive Dermatomyositis. Arthritis & Rheumatology. 2023;75(7):1238-1245. doi:10.1002/art.42474

BibTeX
@article{Fiorentino2023,
  author = {Fiorentino, David and Mecoli, Christopher A and Igusa, Tak and Albayda, Jemima and Paik, Julie J and Tiniakou, Eleni and Adler, Brittany and Mammen, Andrew L and Shah, Ami A and Rosen, Antony and Christopher-Stine, Lisa and Casciola-Rosen, Livia},
  title = {Association of Anti‐CCAR1 Autoantibodies With Decreased Cancer Risk Relative to the General Population in Patients With Anti–Transcriptional Intermediary Factor 1γ–Positive Dermatomyositis},
  journal = {Arthritis & Rheumatology},
  year = {2023},
  volume = {75},
  number = {7},
  pages = {1238--1245},
  doi = {10.1002/art.42474}
}
Kostenlos starten →